Alterity Therapeutics Ltd ADR Dossier - Source-backed chat

Alterity Therapeutics Ltd ADR

ATHAustralian Securities Exchange

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.30

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $3.65Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $66.5M

Enterprise Value $33.5M

Shares Outstanding 18.2M diluted

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Alterity Therapeutics is a late-clinical-stage biopharmaceutical company positioned at the forefront of neurodegenerative disease therapy, specifically targeting Multiple System Atrophy (MSA). The company's lead asset, ATH434, is an oral small-molecule iron chaperone designed to redistribute excess labile iron in the brain, thereby reducing alpha-synuclein aggregation and oxidative stress. Following highly positive Phase 2 clinical trial results—which demonstrated a significant slowing of functional decline (up to 48% on the MuSyCA composite scale) and a favorable safety profile—Alterity is transitioning into a pivotal Phase 3 program. Backed by a strong cash position of A$44.53 million as of March 31, 2026, and active alignment with the FDA, the company presents a compelling high-upside opportunity in an orphan indication with zero approved disease-modifying therapies and an estimated peak global market potential of USD $2.4 billion.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets3 analysts · as of 18 Aug 2026

Low · most bearish analyst$10.00

Mean target$12.67

High · most bullish analyst$16.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$4.0015%

The bear case involves regulatory delays or unexpected FDA requirements during the End-of-Phase 2 meeting, such as demanding additional non-clinical safety studies or a larger, more complex Phase 3 patient cohort. This would accelerate the company's cash burn (operating cash outflow of A$4.73 million per quarter) and force highly dilutive equity raises. Furthermore, failure to secure a strategic partner would leave Alterity solely responsible for funding expensive Phase 3 trials, depressing the stock price toward historical lows.

Base CaseCentral scenario

$12.6760%

Matches the consensus mean

The base case assumes Alterity successfully completes its End-of-Phase 2 meeting with the FDA in mid-2026, establishing a clear and agreed-upon protocol for its pivotal Phase 3 trial of ATH434 in MSA. The company initiates the Phase 3 trial by late 2026 or early 2027. Backed by its current cash runway, Alterity progresses clinical site activation and patient enrollment while simultaneously advancing strategic partnership discussions with global pharmaceutical companies. Efficacy signals from the Phase 2 trials are validated, maintaining strong physician and investor interest.

Bull CaseUpside scenario

$12.0025%

The bull case assumes Alterity rapidly initiates its Phase 3 trial by late 2026, secures a major global pharmaceutical partnership with significant upfront non-dilutive funding, and demonstrates superior efficacy in slowing MSA progression, leading to accelerated FDA approval and rapid commercial uptake.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

First-in-Class Disease-Modifying Potential: ATH434 targets the underlying pathology of MSA (iron accumulation and alpha-synuclein aggregation) where there are currently no approved disease-modifying treatments.
Robust Phase 2 Efficacy Data: Clinical data demonstrated that ATH434 slowed MSA progression by up to 48% on the MuSyCA composite scale, alongside MRI evidence of reduced brain iron and stabilized orthostatic hypotension.
Strong Financial Runway: A cash balance of A$44.53 million as of March 31, 2026, provides approximately 9.4 quarters of funding based on current burn rates, supporting regulatory and clinical milestones.
Favorable Regulatory Status: Granted Fast Track Designation by the FDA, and Orphan Drug Designation by both the FDA and the European Commission, providing market exclusivity and regulatory incentives.

Key Investment Risks

Clinical Development and Phase 3 Execution Risk: Transitioning from Phase 2 to a pivotal Phase 3 trial carries high execution risk, including potential delays in patient recruitment for a rare disease.
Regulatory Hurdles: The upcoming End-of-Phase 2 meeting with the FDA in mid-2026 must successfully align on trial endpoints and protocols; any disagreement could delay initiation.
Funding and Dilution Risk: While the current cash position is strong, a full Phase 3 program is highly capital-intensive, and failure to secure a strategic partner will necessitate future dilutive capital raises.
Competitive Landscape: Other biotechnology and pharmaceutical companies are developing competing candidates targeting alpha-synuclein or MSA symptoms, which could impact future market share.

Thesis Invalidation Triggers

Failure to reach agreement with the FDA on the Phase 3 trial design during the End-of-Phase 2 meeting.
Inability to secure a strategic pharmaceutical partnership or non-dilutive funding within the next 12-18 months, leading to severe equity dilution.
Safety concerns or serious adverse events emerging during the initiation or early stages of the Phase 3 trial.
Clinical trial data from competing pipelines (e.g., Lundbeck's amlenetug) demonstrating superior efficacy or faster regulatory approval paths.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.